AtriCure (NASDAQ:ATRC) Sets New 12-Month High - Here's Why

Key Points

• AtriCure shares reached a new 52-week high of $43.18, up 3.1%, while trading above both its 50-day and 200-day moving averages.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $48.50. The company exceeded quarterly revenue estimates, reporting $153.6 million in revenue and $0.18 in earnings per share.
• Institutional investors own 99.11% of the stock, although insiders have sold 47,246 shares worth approximately $1.78 million over the past 90 days.

AtriCure, Inc. (NASDAQ:ATRC - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday . The company traded as high as $43.18 and last traded at $42.9250, with a volume of 363599 shares trading hands. The stock had previously closed at $41.64.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Wall Street Zen downgraded AtriCure from a "strong-buy" rating to a "buy" rating in a research report on Saturday, May 2nd. Weiss Ratings raised shares of AtriCure from a "sell (e+)" rating to a "sell (d+)" rating in a research note on Tuesday, July 28th. Zacks Research raised shares of AtriCure from a "hold" rating to a "strong-buy" rating in a research note on Friday, July 24th. UBS Group cut their price objective on shares of AtriCure from $55.00 to $50.00 and set a "buy" rating for the company in a research report on Tuesday, July 28th. Finally, Canaccord Genuity Group upped their price objective on shares of AtriCure from $53.00 to $55.00 and gave the company a "buy" rating in a research note on Wednesday, May 6th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, AtriCure presently has a consensus rating of "Moderate Buy" and a consensus target price of $48.50.

AtriCure Stock Up 3.1%

The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. The company has a market cap of $2.18 billion, a PE ratio of 204.53 and a beta of 1.20. The firm has a fifty day simple moving average of $32.56 and a 200 day simple moving average of $31.35.

AtriCure (NASDAQ:ATRC - Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The business had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. During the same period in the prior year, the firm posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Equities research analysts predict that AtriCure, Inc. will post 0.2 EPS for the current year.

Insider Buying and Selling

In related news, Director Maggie Yuen sold 3,500 shares of AtriCure stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $38.42, for a total value of $134,470.00. Following the transaction, the director owned 14,015 shares in the company, valued at approximately $538,456.30. This trade represents a 19.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Vinayak Doraiswamy sold 6,000 shares of the business's stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $38.88, for a total value of $233,280.00. Following the sale, the insider directly owned 86,511 shares of the company's stock, valued at approximately $3,363,547.68. This trade represents a 6.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 47,246 shares of company stock worth $1,777,845 over the last 90 days. Company insiders own 4.00% of the company's stock.

Hedge Funds Weigh In On AtriCure

Several hedge funds and other institutional investors have recently modified their holdings of ATRC. Vanguard Group Inc. grew its stake in AtriCure by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company's stock worth $193,993,000 after buying an additional 62,861 shares during the period. BlackRock Inc. purchased a new stake in AtriCure during the 2nd quarter worth $125,198,000. Wellington Management Group LLP increased its holdings in AtriCure by 8.1% in the 3rd quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company's stock valued at $151,296,000 after purchasing an additional 322,818 shares in the last quarter. First Light Asset Management LLC increased its holdings in AtriCure by 32.0% in the 4th quarter. First Light Asset Management LLC now owns 1,175,445 shares of the medical device company's stock valued at $46,501,000 after purchasing an additional 285,083 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in AtriCure by 8.2% in the first quarter. Dimensional Fund Advisors LP now owns 997,759 shares of the medical device company's stock valued at $28,466,000 after purchasing an additional 75,862 shares during the period. 99.11% of the stock is owned by institutional investors and hedge funds.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company's solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company's product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source